Pricing Log in Create free account
Monday 9 November 2026 Export SLGL’s income statement to Excel — free account

Sol-Gel Technologies Ltd.

SLGL

Healthcare Biotechnology

Sol-Gel Technologies Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $19.4 million, up 68.0% from fiscal 2024.

Revenue
−96.6%
EPS
−127.1%
Free cash flow
−8.76%

Quarter to June 2026, against a year earlier

61.01 2.00 −3.17%
Market cap
$199.8M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
6/9
ROIC
−6,630.2%
Net debt / EBITDA
3.2×
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Net bought
$10.7M
Trades
0 sells · 21 buys
Ownership
59.7%

Capital & Financial Ratios $m

Size
Market Cap 200
Revenue ttm 2
Net income ttm (14)
Free cash flow ttm (21)
Net debt Q (48)
Valuation
P/E n/m
Forward P/E n/m
Price / sales 112.7 (above 10: high)
Forward P/S Powerpack
Price / FCF n/m
Price / book 4.2
Financial health
Current ratio Q 10.4 (at or above 1.5: strong)
Debt / equity Q n/m
Interest coverage Q —
Growth
Revenue growth Q −96.6% (below 0%: shrinking)
Operating income growth Q −137.1% (below 0%: shrinking)
EPS, this year −253.1% (below 0%: weak)
EPS, next year A −16.9% (below 0%: weak)
Revenue, next year A −94.7% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +28.6% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates; n/m is not meaningful, as a P/E on a loss. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 122×, against a ten-year median of 15.3×; over the ten years it ranged from 2.6× in 2025 to 995× in 2019.
P/S against its own 10 years 92.51%
10-year low 10-year high
P/B against its own 10 years 79.07%
10-year low 10-year high
EV/Sales against its own 10 years 92.51%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 28 24 24 48
Receivables 0 4 2 1
Inventory — — — —
Other 10 0 — —
41 31 27 51
2023 2024 2025 Q'26
Payables 0 1 1 1
ST’ Debt — — — —
Other — — — —
5 5 6 5

Compound Annual Growth %

10y 5y 3y
Sales — 17.19% 70.92%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% (14.81%) (18.55%)

Earnings Trends EPS, adjusted, against the consensus

Jun 2026 Estimate −2.31 Actual −1.13

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Sep 2024 −1.30 −0.10 Beat by 1.20
Sep 2025 −2.09 −2.13 Miss by 0.04
Dec 2025 0.39 −1.07 Miss by 1.46
Jun 2026 −2.31 −1.13 Beat by 1.18
Sep 2026 −1.54 — Reports 19 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (1.31) (1.13) — — —
’25 (3.20) 4.17 (2.13) (1.07) (2.19)
’24 (2.30) 0.70 (0.10) (2.10) (3.80)
’23 (4.10) (2.20) (2.10) (1.70) (10.10)
’22 (2.40) (0.06) (1.50) (2.50) (6.50)
’21 (1.80) (3.50) 0.50 6.10 1.40
’20 (3.30) (3.10) (3.70) (2.81) (13.00)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 0 1 — — —
’25 1 17 0 1 19
’24 0 5 5 0 12
’23 0 1 0 0 2
’22 0 4 0 0 4
’21 1 1 9 21 31
’20 3 1 2 2 9
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 — (8) — — —
’25 — 1 — 0 0
’24 — (8) — (14) (14)
’23 — — — — (18)
’22 — — — — (9)
’21 — — — — (8)
’20 — — — — (25)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 — (8) — — —
’25 — 1 — 0 0
’24 — (8) — (14) (14)
’23 — 0 — 0 (18)
’22 — 0 — 0 (10)
’21 — 0 — 0 (8)
’20 — 0 — 0 (26)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — 0 0 23 9 31 4 2 12 19 2 +80.2% 1 1 20 +0.7%
Gross margin, % 0.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 +100.0 pt
EBT (21) (32) (33) (25) (29) 3 (15) (27) (11) (6) (16) (12.7%)
EBT margin, % 0.00 (18,142.53) (25,738.76) (107.30) (333.94) 10.30 (384.32) (1,752.77) (91.70) (31.60) (910.14) (31.6) pt
Net income (21) (32) (32) (25) (29) 3 (15) (27) (11) (6) (14) (12.7%)
Per share, $
Per share, $ Revenue 0.00 0.28 0.07 11.72 3.89 13.56 1.68 0.57 4.14 6.96 0.55 n/m
Earnings (33.00) (50.20) (18.00) (12.60) (13.00) 1.40 (6.50) (10.10) (3.80) (2.19) (5.64) (26.0%)
Cash flow (29.40) (38.30) (13.13) (11.52) (11.18) (3.33) (4.10) (6.55) (4.99) 0.12 (6.49) n/m
Capex (0.61) (3.06) (0.59) (0.31) (0.20) (0.06) (0.07) (0.02) 0.00 0.00 (0.01) n/m
Free cash flow (30.02) (41.36) (13.72) (11.82) (11.38) (3.40) (4.17) (6.57) (4.98) 0.12 (6.50) n/m
Book value (49.82) (83.78) 35.77 26.86 22.52 24.11 18.25 14.27 10.36 8.19 14.70 n/m
Shares, m 1 1 2 2 2 2 2 3 3 3 3 +18.0%
Valuation, ×
Valuation, × P/E — 0.00 0.00 0.00 0.00 52.86 0.00 0.00 0.00 0.00 0.00 5.9
P/S — 0.00 833.84 14.63 25.20 5.46 28.17 21.27 2.25 6.06 112.65 104.1
P/B — 0.00 1.68 6.39 4.35 3.07 2.59 0.86 0.90 5.15 4.20 2.8
EV/Sales — 0.00 859.75 15.28 29.37 6.85 39.56 45.30 5.84 8.19 122.35 112.2
EV/FCF — (3.09) (2.72) (5.03) (3.59) (3.90) (4.32) (1.66) (2.25) (7.70) (10.32) (3.8)
Cash, $m
Cash, $m Operating cash flow (18) (24) (23) (22) (25) (8) (9) (18) (14) 0 (21) n/m
Capex 0 (2) (1) (1) 0 0 0 0 0 0 0 n/m
Free cash flow (19) (26) (25) (23) (26) (8) (10) (18) (14) 0 (21) n/m
Balance, $m
Balance, $m Working capital (33) (57) 61 49 47 45 40 37 26 21 46 n/m
Net debt 30 60 (62) (50) (29) (22) (21) (28) (24) (24) (48) n/m
Shareholders’ equity (31) (53) 64 52 51 56 42 39 29 23 48 n/m
Returns, %
Returns, % ROA (216.04) (240.06) (75.77) (37.58) (48.63) 5.02 (25.77) (59.27) (26.08) (18.63) (35.11) +197.4 pt
ROIC 0.00 (259.63) (1,090.04) (777.13) (85.60) 5.48 (48.15) (171.82) (152.12) 0.00 (6,630.24) 0.0 pt
ROE 96.94 75.13 (574.54) (42.29) (56.70) 6.05 (30.52) (67.37) (31.35) (23.72) (40.85) (120.7) pt
People
People Employees 47 49 56 61 65 53 55 36 34 28 — (5.6%)
Revenue/emp, $m 0.00 0.00 0.00 0.38 0.13 0.59 0.07 0.04 0.34 0.69 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Sol-Gel Technologies Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SLGL Sol-Gel Technologies Ltd. $206.3M — (loss-making) — (loss-making) −96.58% (below 0%: shrinking) n/m −8.76% (below 0%: shrinking) 100.00% (704.23%)
RNAC Cartesian Therapeutics, Inc. $205.1M — (loss-making) — (loss-making) −92.91% (below 0%: shrinking) −7.84% (below 0%: shrinking) −6.15% (below 0%: shrinking) 100.00% 0.00% Compare
DRUG Bright Minds Biosciences Inc. $204.2M — (loss-making) — — n/m −124.63% (below 0%: shrinking) 0.00% 0.00% Compare
PLX Protalix BioTherapeutics, Inc. $202.2M 10.5× 10.6× +27.07% (above 0%: growing) +2,280.95% (above 0%: growing) −94.09% (below 0%: shrinking) 60.99% 23.48% Compare
PALI Palisade Bio, Inc. $202.2M 1.8× — (loss-making) +19,900.00% (above 0%: growing) n/m −318.44% (below 0%: shrinking) 100.00% (2,339.60%) Compare
ARTV Artiva Biotherapeutics, Inc. $201.9M — (loss-making) — (loss-making) — n/m +13.60% (above 0%: growing) 100.00% 0.00% Compare
IKT Inhibikase Therapeutics, Inc. $200.9M — (loss-making) — (loss-making) −100.00% (below 0%: shrinking) n/m −123.23% (below 0%: shrinking) 0.00% 0.00% Compare
ELDN Eledon Pharmaceuticals, Inc. $199.9M — (loss-making) — — n/m −28.02% (below 0%: shrinking) 0.00% 0.00% Compare
IFRX InflaRx N.V. $199.7M — (loss-making) — (loss-making) −128.93% (below 0%: shrinking) n/m +59.76% (above 0%: growing) 14,029.95% 0.00% Compare
Median of peers $202.0M — — −92.91% — −61.05% 80.50% 0.00%

All 621 Biotechnology stocks →

Sol-Gel Technologies Ltd. (SLGL) Latest News

14 Oct

Impact 4 · · MarketBeat

8 Oct

Impact 3 · · Zacks

30 Sep

Impact 3 · · GlobeNewswire

17 Sep

Impact 4 ·
Impact 4 · · Zacks

20 Aug

Impact 3 ·

28 May

Impact 3 · · Zacks
Impact 3 · · GlobeNewswire

23 Mar

Impact 4 · · GlobeNewswire

19 Mar

Impact 3 · · Zacks

11 Feb

Impact 4 · · Simply Wall St.24/7 Wall St.Motley FoolBarchartMotley Fool24/7 Wall St.Motley FoolGOBankingRates

29 Dec

Impact 4 · · Simply Wall St.

17 Dec

Impact 4 ·

20 Nov

Impact 4 · · Zacks
Impact 3 · · GlobeNewswire

10 Nov

Impact 3 ·

4 Sep

Impact 4 · · Simply Wall St.
Impact 4 · · GlobeNewswire

15 Aug

Impact 3 · · GlobeNewswire

22 Jul

Impact 3 ·

23 May

Impact 3 · · GlobeNewswire

2 May

Impact 3 · · Simply Wall St.

1 May

Impact 4 ·

17 Apr

Impact 4 · · GlobeNewswire

25 Feb

Impact 3 · · Zacks

7 Feb

Impact 3 · · Simply Wall St.

25 Dec

Impact 4 · · Zacks

17 Nov

Impact 4 ·

15 Nov

Impact 4 · · GlobeNewswire

27 Aug

Impact 4 · · Zacks
stockrow.com/SLGL · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com